|
1.
|
|
13 p, 1.4 MB |
Contribution of cystatin C- and creatinine-based definitions of chronic kidney disease to cardiovascular risk assessment in 20 population-based and 3 disease cohorts : the BiomarCaRE project
/
Rothenbacher, Dietrich (German Cancer Research Center (DKFZ)) ;
Rehm, Martin (Ulm University) ;
Iacoviello, Licia (University of Insubria (Itàlia)) ;
Costanzo, Simona (Istituto Neurologico Mediterraneo Neuromed (Itàlia)) ;
Tunstall-Pedoe, Hugh (University of Dundee) ;
Belch, Jill J.F. (University of Dundee) ;
Söderberg, Stefan (Umeå University) ;
Hultdin, Johan (Umeå University) ;
Salomaa, Veikko (Finnish Institute for Health and Welfare) ;
Jousilahti, Pekka (Finnish Institute for Health and Welfare) ;
Linneberg, Allan (Bispebjerg and Frederiksberg Hospital) ;
Sans, Susana (Institut Català de la Salut (Barcelona)) ;
Padró, Teresa (Institut d'Investigació Biomèdica Sant Pau) ;
Thorand, Barbara (German Research Center for Environmental Health) ;
Meisinger, C. (Chair of Epidemiology at UNIKA-T Augsburg) ;
Kee, Frank (Queen's University of Belfast) ;
McKnight, Amy Jayne (Queen's University of Belfast) ;
Palosaari, Tarja (Finnish Institute for Health and Welfare) ;
Kuulasmaa, Kari (Finnish Institute for Health and Welfare) ;
Waldeyer, Christoph (University Heart Center Hamburg) ;
Zeller, Tanja (German Center for Cardiovascular Research (DZHK e.V.)) ;
Blankenberg, Stefan (German Center for Cardiovascular Research (DZHK e.V.)) ;
Koenig, Wolfgang (DZHK (German Centre for Cardiovascular Research)) ;
Universitat Autònoma de Barcelona
Chronic kidney disease has emerged as a strong cardiovascular risk factor, and in many current guidelines, it is already considered as a coronary heart disease (CHD) equivalent. Routinely, creatinine has been used as the main marker of renal function, but recently, cystatin C emerged as a more promising marker. [...]
2020 -  10.1186/s12916-020-01776-7
BMC Medicine, Vol. 18 Núm. 1 (december 2020) , p. 300
|
|
|
2.
|
|
0 p, 533.7 KB |
Longitudinal association of dietary acid load with kidney function decline in an older adult population with metabolic syndrome
/
Valle-Hita, Cristina (Instituto de Salud Carlos III) ;
Becerra-Tomás, Nerea (Imperial College London) ;
Díaz-López, Andrés (Universitat Rovira i Virgili) ;
Vázquez-Ruiz, Zenaida (Universidad de Navarra) ;
Megías, Isabel (Universitat Rovira i Virgili) ;
Corella, Dolores (Universitat de València) ;
Goday Arnó, Albert (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Martínez, J. Alfredo (Institutos Madrileño de Estudios Avanzados) ;
Alonso-Gómez, Ángel María (Osakidetza) ;
Wärnberg, Julia (Universidad de Málaga) ;
Vioque, Jesús (Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública) ;
Romaguera, Dora (Institut d'Investigació Sanitària Illes Balears) ;
López-Miranda, José (Universidad de Córdoba) ;
Estruch, Ramón (Hospital Clínic i Provincial de Barcelona) ;
Tinahones, Francisco J.. (Instituto de Investigación Biomédica de Málaga) ;
Lapetra, José (Distrito Sanitario Atención Primaria Sevilla) ;
Serra-Majem, Luís (Centro Hospitalario Universitario Insular Materno Infantil) ;
Bueno-Cavanillas, Aurora (Universidad de Granada) ;
Tur, Josep A. (Universidad de Balearic Islands) ;
Martín-Sánchez, Vicente (Universidad de León) ;
Pintó, Xavier (Institut d'Investigació Biomèdica de Bellvitge) ;
Gaforio, José J. (Universidad de Jaén) ;
Matía-Martín, Pilar (Universidad Complutense de Madrid) ;
Vidal, Josep (Hospital Clínic i Provincial de Barcelona) ;
Amengual-Galbarte, Angela (Hospital Universitario Rey Juan Carlos (Madrid)) ;
Daimiel, Lidia (Institutos Madrileño de Estudios Avanzados) ;
Ros, Emilio (Hospital Clínic i Provincial de Barcelona) ;
García-Arellano, Ana (Hospital Universitario de Navarra) ;
Barragán, Rocío (Universitat de València) ;
Fitó, Montserrat (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Peña-Orihuela, Patricia J. (Universidad de Córdoba) ;
Asencio-Aznar, Alberto (Centro de Salud Muchamiel) ;
Gómez-Gracia, Enrique (Instituto de Investigación Biomédica de Málaga) ;
Martinez-Urbistondo, Diego (Clínica Universidad de Navarra) ;
Morey, Marga (Institut d'Investigació Sanitària Illes Balears) ;
Casas, Rosa (Hospital Clínic i Provincial de Barcelona) ;
Garrido-Garrido, Eva María (Servicio Andaluz de Salud) ;
Tojal-Sierra, Lucas (Osakidetza) ;
Damas-Fuentes, Miguel (Instituto de Investigación Biomédica de Málaga) ;
Goñi, Estibaliz (Instituto de Investigación Sanitaria de Navarra) ;
Ortega-Azorín, Carolina (Universitat de València) ;
Castañer, Olga (Institut Hospital del Mar d'Investigacions Mèdiques) ;
García-Rios, Antonio (Universidad de Córdoba) ;
Gisbert-Sellés, Cristina (Centre de Salut de Sant Vicent del Raspeig) ;
Sayón-Orea, Carmen (Universidad de Navarra) ;
Schröder, Helmut (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Salas-Salvadó, Jordi (Instituto de Salud Carlos III) ;
Babio, Nancy (Instituto de Salud Carlos III) ;
Universitat Autònoma de Barcelona
Diets high in acid load may contribute to kidney function impairment. This study aimed to investigate the association between dietary acid load and 1-year changes in glomerular filtration rate (eGFR) and urine albumin/creatinine ratio (UACR). [...]
2022 - 10.3389/fnut.2022.986190
Frontiers in nutrition, Vol. 9 (september 2022)
|
|
|
3.
|
|
15 p, 935.7 KB |
Augmented renal clearance. An unnoticed relevant event
/
Tomasa-Irriguible, Teresa Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Sabater-Riera, Joan (Hospital Universitari de Bellvitge) ;
Pérez-Carrasco, Marcos (Hospital Universitari Vall d'Hebron) ;
Ortiz-Ballujera, Patricia (Hospital Universitari de Girona Doctor Josep Trueta) ;
Díaz Buendia, Yolanda (Hospital del Mar (Barcelona, Catalunya)) ;
Navas Pérez, Ana Maria (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Betbesé Roig, Antoni Jordi (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Rodríguez-López, Miguel (Hospital de Sant Joan Despí Moisès Broggi) ;
Ibarz, Mercedes (Hospital del Sagrat Cor (Barcelona, Catalunya)) ;
Olmo-Isasmendi, Aitor (Hospital Universitari General de Catalunya) ;
Oliva-Zelaya, Iban (Hospital Universitari Joan XXIII de Tarragona) ;
Rovira-Anglès, Conxita (Hospital Universitari Sant Joan de Reus (Tarragona)) ;
Cano Hernández, Silvia (Fundació Althaia (Manresa, Catalunya)) ;
Vendrell-Torra, Ester (Hospital de Mataró. Consorci Sanitari del Maresme) ;
Catalan-Ibars, Rosa-María (Consorci Hospitalari de Vic) ;
Miralbés-Torner, Mar (Hospital Arnau de Vilanova (Lleida, Catalunya)) ;
González de Molina, Francisco Javier (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Xirgu-Cortacans, Judith (Hospital General de Granollers) ;
Marcos Neira, Pilar (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Augmented renal clearance (ARC) is a phenomenon that can lead to a therapeutic failure of those drugs of renal clearance. The purpose of the study was to ascertain the prevalence of ARC in the critically ill patient, to study the glomerular filtration rate (GFR) throughout the follow-up and analyze the concordance between the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) estimation formula and measured GFR. [...]
2021 - 10.1177/00368504211018580
Science Progress, Vol. 104 Núm. 2 (2021)
|
|
|
4.
|
|
16 p, 628.4 KB |
Glycaemic Control with Insulin Glargine 300 U/mL in Individuals with Type 2 Diabetes and Chronic Kidney Disease : A REALI European Pooled Data Analysis
/
Mauricio Puente, Dídac (Institut d'Investigació Biomèdica Sant Pau) ;
Gourdy, P. (Institute of Metabolic and Cardiovascular Diseases. UMR1048 INSERM/UPS. Toulouse University) ;
Bonadonna, Riccardo C (Department of Medicine and Surgery. University of Parma) ;
Freemantle, N. (Institute of Clinical Trials and Methodology. University College London) ;
Bigot, Gregory (IVIDATA) ;
Mauquoi, C. (IDDI) ;
Ciocca, A. (General Medicines. Sanofi) ;
Bonnemaire, Mireille (General Medicines. Sanofi) ;
Müller-Wieland, D. (Department of Medicine I. University Hospital Aachen)
Introduction: Management of type 2 diabetes mellitus (T2DM) in patients with chronic kidney disease is complex. Using the REALI European pooled database, we determined the impact of baseline renal function on the effectiveness and safety of insulin glargine 300 U/mL (Gla-300) initiated in adults with inadequately controlled T2DM. [...]
2021 - 10.1007/s13300-021-01031-z
Diabetes Therapy, Vol. 12 Núm. 4 (april 2021) , p. 1159-1174
|
|
|
5.
|
|
9 p, 2.6 MB |
A Specific Tubular ApoA-I Distribution Is Associated to FSGS Recurrence after Kidney Transplantation
/
Jacobs-Cachá, Conxita (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Puig-Gay, Natalia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Vergara, Ander (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Gabaldon, Maria-Alejandra (Hospital Universitari Vall d'Hebron) ;
Sellarés, Joana (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Villena-Ortiz, Yolanda (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Agraz Pamplona, Irene (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Moreso, Francesc (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Soler, María José (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Seron, Daniel (Universitat Autònoma de Barcelona. Departament de Medicina) ;
López-Hellín, Joan (Hospital Universitari Vall d'Hebron. Institut de Recerca)
A major complication of primary focal segmental glomerulosclerosis (FSGS) is its recurrence after kidney transplantation that happens in 30 to 40% of the patients. The diagnosis of these relapses is not always easy as the histological lesions are not highly specific and appear after the proteinuria increase. [...]
2021 - 10.3390/jcm10102174
Journal of clinical medicine, Vol. 10 (may 2021)
|
|
|
6.
|
|
10 p, 2.0 MB |
Analysis of Renal and Cardiac Outcomes in Male Participants in the Fabry Outcome Survey Starting Agalsidase Alfa Enzyme Replacement Therapy Before and After 18 Years of Age
/
Parini, Rossella (Istituto di Ricovero e Cura A Carattere Scientifico (IRCCS)) ;
Pintos-Morell, Guillem (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Hennermann, Julia B. (University Medical Center) ;
Hsu, Ting-Rong (Taipei Veterans General Hospital) ;
Karabul, Nesrin (University Children's Hospital and Centre for Rare Diseases) ;
Kalampoki, Vasiliki (Shire (Suïssa)) ;
Gurevich, Andrey (Shire (Suïssa)) ;
Ramaswami, Uma (Royal Free London NHS Foundation Trust) ;
Universitat Autònoma de Barcelona
To determine the impact of initiating enzyme replacement therapy (ERT) with agalsidase alfa early in the course of Fabry disease, we evaluated renal and cardiac outcomes for ≤10 years after ERT initiation in males from the Fabry Outcome Survey (FOS). [...]
2020 - 10.2147/DDDT.S249433
Drug Design, Development and Therapy, Vol. 14 (june 2020) , p. 2149-2158
|
|
|
7.
|
|
9 p, 745.9 KB |
Long-term follow-up of renal function in patients treated with migalastat for Fabry disease
/
Bichet, Daniel G. (Department of Medicine, Hôpital du Sacré-Coeur, University of Montréal, Montreal, Quebec, Canada) ;
Torra Balcells, Roser (Institut d'Investigació Biomèdica Sant Pau) ;
Wallace, Eric (Department of Medicine, University of Alabama, Birmingham, AL, USA) ;
Hughes, Derralynn A (Lysosomal Storage Disorders Unit, Royal Free London NHS Foundation Trust and University College London, London, UK) ;
Giugliani, Roberto (Instituto Nacional de Genética Médica Populacional (Porto Alegre, Brasil)) ;
Skuban, Nina (Amicus Therapeutics, Inc., Cranbury, NJ, USA) ;
Krusinska, Eva (Amicus Therapeutics, Inc., Cranbury, NJ, USA) ;
Feldt-Rasmussen, Ulla (Copenhagen University Hospital Rigshospitalet) ;
Schiffmann, Raphael (Institute of Metabolic Disease, Baylor Scott & White Research Institute, Dallas, TX, USA) ;
Nicholls, Kathy (Royal Melbourne Hospital (Melbourne, Austràlia)) ;
Universitat Autònoma de Barcelona
The effect of migalastat on long-term renal outcomes in enzyme replacement therapy (ERT)-naive and ERT-experienced patients with Fabry disease is not well defined. An integrated posthoc analysis of the phase 3 clinical trials and open-label extension studies was conducted to evaluate long-term changes in renal function in patients with Fabry disease and amenable GLA variants who were treated with migalastat for ≥2 years during these studies. [...]
2021 - 10.1016/j.ymgmr.2021.100786
Molecular Genetics and Metabolism Reports, Vol. 28 (august 2021)
|
|
|
8.
|
|
5 p, 246.4 KB |
Long-term outcomes with agalsidase alfa enzyme replacement therapy : analysis using deconstructed composite events
/
Beck, Michael (University Medical Center, Mainz, Germany) ;
Hughes, Derralynn A (University College London) ;
Kampmann, Christoph (University Medical Center, Mainz, Germany) ;
Pintos-Morell, Guillem (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ramaswami, Uma (University College London) ;
West, Michael L. (Dalhousie University, Halifax, Canada) ;
Giugliani, Roberto (Universidade Federal do Rio Grande do Sul, Brazil) ;
Universitat Autònoma de Barcelona
This is a retrospective analysis of Fabry Outcome Survey data from children/adults (n = 677) receiving agalsidase alfa enzyme replacement therapy for a median of 3 years, examining cerebrovascular, cardiac, and renal morbidity endpoints separately. [...]
2017 - 10.1016/j.ymgmr.2017.10.008
Molecular Genetics and Metabolism Reports, Vol. 14 (november 2017) , p. 31-35
|
|
|
9.
|
|
9 p, 951.7 KB |
Comparative differential proteomic analysis of minimal change disease and focal segmental glomerulosclerosis
/
Pérez Jiménez, Vanessa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
López, Dolores (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Boixadera Planas, Ester (Universitat Autònoma de Barcelona. Servei d'Estadística Aplicada) ;
Ibernon, Meritxell (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Espinal Berenguer, Anna (Universitat Autònoma de Barcelona. Servei d'Estadística Aplicada) ;
Bonet Sol, Josep (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Romero, Ramón (Universitat Autònoma de Barcelona. Departament de Medicina)
Minimal change disease (MCD) and primary focal segmental glomerulosclerosis (FSGS) are glomerular diseases characterized by nephrotic syndrome. Their diagnosis requires a renal biopsy, but it is an invasive procedure with potential complications. [...]
2017 - 10.1186/s12882-017-0452-6
BMC Nephrology, Vol. 18 (February 2017) , art. 49
|
|
|
10.
|
|
7 p, 412.7 KB |
Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease : A Fabry Outcome Survey analysis
/
Beck, Michael (University Medical Center, University of Mainz, Department of Paediatrics) ;
Hughes, Derralynn A (Royal Free London NHS Foundation Trust, University College of London) ;
Kampmann, Christoph (University Medical Center, University of Mainz, Department of Paediatrics) ;
Larroque, Sylvain (Shire, Zug) ;
Mehta, Atul (Royal Free London NHS Foundation Trust, University College of London) ;
Pintos-Morellell, Guillem (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ramaswami, Uma (Royal Free London NHS Foundation Trust, University College of London) ;
West, Michael (Department of Medicine, Dalhousie University) ;
Wijatyk, Anna (Shire) ;
Giugliani, Roberto (Medical Genetics Service HCPA/Dep Genet UFRGS and INAGEMP, Porto Alegre) ;
Universitat Autònoma de Barcelona
Outcomes from 5 years of treatment with agalsidase alfa enzyme replacement therapy (ERT) for Fabry disease in patients enrolled in the Fabry Outcome Survey (FOS) were compared with published findings for untreated patients with Fabry disease. [...]
2015 - 10.1016/j.ymgmr.2015.02.002
Molecular Genetics and Metabolism Reports, Vol. 3 (march 2015) , p. 21-27
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
